Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities

Lateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symp...

Full description

Bibliographic Details
Main Authors: Khayriyyah Mohd Hanafiah, Norsyahida Arifin, Yazmin Bustami, Rahmah Noordin, Mary Garcia, David Anderson
Format: Article
Language:English
Published: MDPI AG 2017-09-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/7/3/51
id doaj-b1032ecf35b74875afbb98c89b9761bf
record_format Article
spelling doaj-b1032ecf35b74875afbb98c89b9761bf2020-11-24T21:54:11ZengMDPI AGDiagnostics2075-44182017-09-01735110.3390/diagnostics7030051diagnostics7030051Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and OpportunitiesKhayriyyah Mohd Hanafiah0Norsyahida Arifin1Yazmin Bustami2Rahmah Noordin3Mary Garcia4David Anderson5School of Biological Sciences, Universiti Sains Malaysia, Penang 11800, MalaysiaInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, MalaysiaSchool of Biological Sciences, Universiti Sains Malaysia, Penang 11800, MalaysiaInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, MalaysiaLife Sciences, Macfarlane Burnet Institute, Melbourne 3004, AustraliaLife Sciences, Macfarlane Burnet Institute, Melbourne 3004, AustraliaLateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symptoms and states of co-infections, there is increasing demand for multiplexed systems that can detect multiple biomarkers simultaneously. Due to innate limitations in the design of traditional membrane-based LFAs, multiplexing is arguably limited to a small number of biomarkers. Here, we summarize the need for multiplexed LFA, key technical and operational challenges for multiplexing, inherent in the design and production of multiplexed LFAs, as well as emerging enabling technologies that may be able to address these challenges. We further identify important areas for research in efforts towards developing multiplexed LFAs for more impactful diagnosis of infectious diseases.https://www.mdpi.com/2075-4418/7/3/51lateral flow assaypoint-of-caremultiplexdiagnostic testinfectious diseaseresource-limited settings
collection DOAJ
language English
format Article
sources DOAJ
author Khayriyyah Mohd Hanafiah
Norsyahida Arifin
Yazmin Bustami
Rahmah Noordin
Mary Garcia
David Anderson
spellingShingle Khayriyyah Mohd Hanafiah
Norsyahida Arifin
Yazmin Bustami
Rahmah Noordin
Mary Garcia
David Anderson
Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
Diagnostics
lateral flow assay
point-of-care
multiplex
diagnostic test
infectious disease
resource-limited settings
author_facet Khayriyyah Mohd Hanafiah
Norsyahida Arifin
Yazmin Bustami
Rahmah Noordin
Mary Garcia
David Anderson
author_sort Khayriyyah Mohd Hanafiah
title Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
title_short Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
title_full Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
title_fullStr Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
title_full_unstemmed Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
title_sort development of multiplexed infectious disease lateral flow assays: challenges and opportunities
publisher MDPI AG
series Diagnostics
issn 2075-4418
publishDate 2017-09-01
description Lateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symptoms and states of co-infections, there is increasing demand for multiplexed systems that can detect multiple biomarkers simultaneously. Due to innate limitations in the design of traditional membrane-based LFAs, multiplexing is arguably limited to a small number of biomarkers. Here, we summarize the need for multiplexed LFA, key technical and operational challenges for multiplexing, inherent in the design and production of multiplexed LFAs, as well as emerging enabling technologies that may be able to address these challenges. We further identify important areas for research in efforts towards developing multiplexed LFAs for more impactful diagnosis of infectious diseases.
topic lateral flow assay
point-of-care
multiplex
diagnostic test
infectious disease
resource-limited settings
url https://www.mdpi.com/2075-4418/7/3/51
work_keys_str_mv AT khayriyyahmohdhanafiah developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities
AT norsyahidaarifin developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities
AT yazminbustami developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities
AT rahmahnoordin developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities
AT marygarcia developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities
AT davidanderson developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities
_version_ 1725868302414118912